JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Home・Akcijų sąrašas・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Uždarymo kaina

3.35 -1.18

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.34

Max

3.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -25M
Pardavimai	190K 1.8M
Pelno marža	-1,390.363
Darbuotojai	44
EBITDA	-12M -24M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+2.94% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.8M 640M
Ankstesnė atidarymo kaina	4.53
Ankstesnė uždarymo kaina	3.35

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

3.255 / 3.365 Palaikymas ir pasipriešinimas

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-11 17:49; UTC

Pagrindinės rinkos jėgos

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025-08-11 17:18; UTC

Pagrindinės rinkos jėgos

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025-08-11 16:25; UTC

Uždarbis

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025-08-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025-08-11 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025-08-11 23:32; UTC

Rinkos pokalbiai

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025-08-11 23:02; UTC

Rinkos pokalbiai

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025-08-11 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement 2Q Rev $25.8M >EXOD

2025-08-11 20:14; UTC

Rinkos pokalbiai

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025-08-11 19:12; UTC

Rinkos pokalbiai

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025-08-11 18:56; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025-08-11 18:31; UTC

Rinkos pokalbiai

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025-08-11 17:43; UTC

Rinkos pokalbiai

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025-08-11 17:28; UTC

Rinkos pokalbiai

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025-08-11 17:16; UTC

Rinkos pokalbiai

Commodity Longs Fall to 11-Month Low -- Market Talk

2025-08-11 16:42; UTC

Įsigijimai, susijungimai, perėmimai

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025-08-11 16:27; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Says Sabadell Offer Remains in Effect

2025-08-11 16:26; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Announced TSB Sale on July 1

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Kainos tikslas

By TipRanks

2.94% į viršų

12 mėnesių prognozė

Vidutinis 3.5 USD 2.94%

Aukščiausias 3.5 USD

Žemiausias 3.5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arbutus Biopharma Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Arbutus Biopharma Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.